SCHEMBL3319710

SCHEMBL3319710

CC(O)c1ncnn1Cc1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 2/20 0.49
NPC1 O15118 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
P2RX7 Q99572 1/20 0.44
ALDH1A1 P00352 3/20 0.43
HPGD P15428 3/20 0.43
LMNA P02545 2/20 0.43
HTT P42858 2/20 0.43
PKM P14618 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
TSHR P16473 2/20 0.42
MAPK1 P28482 2/20 0.42
POLB P06746 2/20 0.40
HDAC1 Q13547 1/20 0.40
HDAC6 Q9UBN7 1/20 0.40
SLC9A1 P19634 1/20 0.39
GRM2 Q14416 1/20 0.39
RECQL P46063 1/20 0.39
HSD17B10 Q99714 1/20 0.38
CYP19A1 P11511 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5732991 1.00 RAB9A (0.49) RAB9ANPC1SMN1; SMN2P2RX7ALDH1A1
SCHEMBL20569205 0.91 HDAC1 (0.45) RAB9ANPC1SMN1; SMN2P2RX7ALDH1A1
SCHEMBL3323347 0.88 SMN1; SMN2 (0.47) RAB9ANPC1SMN1; SMN2P2RX7ALDH1A1
SCHEMBL5731482 0.88 SMN1; SMN2 (0.47) RAB9ANPC1SMN1; SMN2P2RX7ALDH1A1
SCHEMBL5731641 0.86 HTT (0.52) RAB9ANPC1SMN1; SMN2ALDH1A1LMNA
SCHEMBL3320689 0.86 HTT (0.52) RAB9ANPC1SMN1; SMN2ALDH1A1LMNA
SCHEMBL3318864 0.82 SMN1; SMN2 (0.44) RAB9ANPC1SMN1; SMN2P2RX7ALDH1A1
SCHEMBL5807714 0.82 SMN1; SMN2 (0.44) RAB9ANPC1SMN1; SMN2P2RX7ALDH1A1
SCHEMBL5732994 0.76 RAB9A (0.39) RAB9ANPC1SMN1; SMN2P2RX7ALDH1A1
SCHEMBL5731486 0.75 RAB9A (0.36) RAB9ANPC1SMN1; SMN2P2RX7ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100144812-A1 Heterocyclic Sulfonamide Inhibitors of Beta Amyloid Production Containing an Azole WYETH LLP (US) 2010-06-10 US disclosed
US-7674813-B2 Heterocyclic sulfonamide inhibitors of beta amyloid production containing an azole WYETH (US) 2010-03-09 US disclosed
EP-1709003-B1 HETEROCYCLIC SULFONAMIDE INHIBITORS OF BETA AMYLOID PRODUCTION CONTAINING AN AZOLE WYETH CORP (US) 2009-09-23 EP disclosed
US-20080249150-A1 HETEROCYCLIC SULFONAMIDE INHIBITORS OF BETA AMYLOID PRODUCTION CONTAINING AN AZOLE WYETH (US) 2008-10-09 US disclosed
US-7399778-B2 Heterocyclic sulfonamide inhibitors of beta amyloid production containing an azole WYETH (US) 2008-07-15 US disclosed
CN-1910158-A Heterocyclic sulfonamide inhibitors of beta amyloid production containing an azole WYETH CORP (US) 2007-02-07 CN disclosed
US-20050171180-A1 Heterocyclic sulfonamide inhibtors of beta amyloid production containing an azole WYETH (US) 2005-08-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144812-A1 Heterocyclic Sulfonamide Inhibitors of Beta Amyloid Production Containing an Azole APP, IAPP, PARK7 RAB9A 2912/4885NPC1 3012/4885SMN1; SMN2 971/4885
US-20080249150-A1 HETEROCYCLIC SULFONAMIDE INHIBITORS OF BETA AMYLOID PRODUCTION CONTAINING AN AZOLE APP, IAPP, PARK7 RAB9A 2912/4885NPC1 3012/4885SMN1; SMN2 971/4885
US-20050171180-A1 Heterocyclic sulfonamide inhibtors of beta amyloid production containing an azole IAPP, APP, CBR3 RAB9A 3255/4885NPC1 3832/4885SMN1; SMN2 1638/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.